Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer

Current Opinion in Oncology

Volumn 22, Issue 2, 2010, Pages 102-111

  De Craene, Sofie ^a   Surmont, Veerle ^a,b   Van Meerbeeck, Jan P ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Lung Oncological Network Ghent (LONG)   (Belgium)

Author keywords

Chemotherapy; Combined modality; Radiotherapy; Stage IIIA N2; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; NAVELBINE; PACLITAXEL; THALIDOMIDE;

ADJUVANT CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; FEBRILE NEUTROPENIA; HUMAN; LUNG BIOPSY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PNEUMONECTOMY; RADIOTHERAPY;

EID: 76749157190     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328335c076     Document Type: Review

References (42)

1. Johnson DH, Rusch VW, Turrisi T. Scalpels, beams, drugs and dreams: challenges of stage IIIA-N2 nonsmall-cell lung cancer. J Natl Cancer Inst 2007; 99:415-418.
2. Van Meerbeeck JP, Surmont V. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments. Lung Cancer 2009; 65:257-267.
3. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatinum evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552-3559.
4. Lim E, Harris G, Patel A, et al. Preoperative versus postoperative chemotherapy in patients with resectable nonsmall cell lung cancer: systematic review and indirect comparison meta-analysis of randomised trials. J Thorac Oncol 2008; 3:S56; abstract 1500.
5. Stewart LA, Burdett S, Tierney JF, et al. A meta-analysis using individual patient data from randomised clinical trials (RCT). J Clin Oncol 2007; 25:397s; abstr 75552.
6. PORT meta-analysis Trialists Group. Postoperative radiotherapy for nonsmall cell lung cancer (Cochrane Review). The Cochrane Library 2005. Oxford: Update Software.
7. Douillard JY, Rossell R, De Lena M, et al. Adjuvant vinorelbine pluscisplatin versus observation in patients with completely resected stage IB-IIIA nonsmall cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719-727.
8. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III nonsmall cell lung cancer using the Surveillance Epidemiology and End Results Database. J Clin Oncol 2006; 24:2998-3006.
9. Robinson L, Ruckdeschel J, Wagner H, et al. Treatment of nonsmall cell lung cancer-stage IIIA. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:243S-265S. (Pubitemid 47502811)
10. Burdett S, Stewart L, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in nonsmall cell lung cancer. J Thorac Oncol 2006; 1:611-621.
11. Dan L, Zhu B, Chen Z. Meta-analysis of the literature: neoadjuvant chemotherapy versus surgery alone in nonsmall cell lung cancer [abstract 7580]. J Clin Oncol 2008; 26.
12. Mansour Z, Kochetkova EA, Santelmo N, et al. Persistent N2 disease after induction chemotherapy does not jeopardize early and medium term outcomes of pneumonectomy. Ann Thorac Surg 2008; 86:228-233.
13. Carretta A, Ciriaco P, Melloni G, et al. Results of surgical treatment after neoadjuvant chemotherapy for stage III nonsmall cell lung cancer. World J Surg 2008; 32:2636-2642.
14. Yap S-P, Lim W-T, Foo K-F, et al. Induction concurrent chemoradiotherapy using paclitaxel and carboplatin combination followed by surgery in loco-regionally advanced nonsmall cell lung cancer: Asian Experience. Ann Acad Med Singapore 2008; 37:377-382.
15. Edelman MJ, Suntharalingam M, Burrows W, et al. Phase I/II trial of hyper-fractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg 2008; 86:903-911.
16. Dudek AZ, Lesniewski-Kmak K, Larson T, et al. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III nonsmall cell lung cancer. J Thorac Oncol 2009; 4:969-975.
17. Albain S, Swann S, Rush V, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III nonsmall cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374:379-386.
18. Thomas M, RübeC, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III nonsmall-cell lung cancer. Lancet Oncol 2008; 9:636-648.
19. Felip E, Massuti B, Alonso JL, et al. Surgery alone, or surgery followed by adjuvant (adj) paclitaxel/carboplatin (PC) chemotherapy (CT) or preoperative (preop) PC followed by surgery, in early stage nonsmall cell lung cancer: results of a multicenter, randomized, phase III NATCH trial. J Clin Oncol 2009; 27:15s. (suppl; abstr 7500).
20. Westeel V, Milleron B, Quoix E, et al. Results of the IFCT0002 phase III study comparing a preoperative and a perioperative chemotherapy (CT) with two different CT regimens in resectable nonsmall cell lung cancer (NSCLC). J Clin Oncol 2009; 27:15s. (suppl; abstr 7530).
21. Vandenbroucke E, De Ryck F, Surmont V, et al. What is the role of surgery in patients with stage III nonsmall cell lung cancer? CurrOpin Pulm Med 2009; 15:295-302.
22. Belani CP, Wang W, Johnson DH, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B nonsmall cell lung cancer. J Clin Oncol 2005; 23:3760-3767.
23. CarreteroC, Saenz G, LaribbaG, et al. Adjuvant chemotherapy for early-stage nonsmall-cell lung cancer. Single-centre experience and literature review. Clin Transl Oncol 2008; 10:560-571.
24. Tibaldi C, Mazzoni E, Arcabasso G, et al. Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected nonsmall cell lung cancer: a pilot study. Clin Lung Cancer 2009; 10:53-57.
25. Stinchcombe TE, Harper HD, Hensing TA, et al. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected nonsmall cell lung cancer. J Thorac Oncol 2008; 3:145-151.
26. Gottfried M, Ramlou R, Krzakowski M, et al. Cisplatinum-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced nonsmall cell lung cancer. Final results. J Thorac Oncol 2008; 3:152-157.
27. Sobin L, Gospodarowicz M, Wittekin C. UICC. TNM classification of malignant tumours. 7th ed. ISBN 978-1-4443-3241-4.
28. Margaritora S, Cesario A, Galetta D, et al. A year experience with induction therapy in locally advanced nonsmall cell lung cancer (NSCLC): is clinical re-staging predictive of pathologic staging? Eur J Cardiothorac Surg 2001; 19:894-898.
29. Vansteenkiste JF, Stroobants SG, Deleyn PR, et al. Potential use of FDG-PET after induction chemotherapy in surgically staged IIIA-N2 nonsmall cell lung cancer. A prospective pilot study. Ann Oncol 1998; 9:1193-1198.
30. Hoekstra C, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced nonsmall cell lung cancer. J Clin Oncol 2005; 23:8362-8370.
31. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIA) nonsmall cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 2006; 131:1229-1235.
32. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 nonsmall cell lung cancer: a Leuven Lung Cancer Group study. J Clin Oncol 2006; 24:3333-3339.
33. Varadarajulu S, Eloubeidi M. Can endoscopic ultrasonography-guided fine needle aspiration predict response to chemoradiation in nonsmall cell lung cancer? Respiration 2006; 73:213-220.
34. Herth FJF, Annema JT, Eberhardt R, et al. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. J Clin Oncol 2008; 26:3346-3350.
35. Pass HI. Lung cancer staging techniques and induction therapy: maybe timing is everything. J Clin Oncol 2008; 28:3306-3307.
36. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III nonsmall cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26:2450-2456
37. Phase III comparison of postoperative 3D conform radiotherapy after chemotherapy and chemotherapy alone in patients with completely resected stage IIIA(N2) nonsmall cell lung cancer. http://www.clinicaltrialsgov/ NCT00880971 [Accessed April 2009].
38. Page BR, Blitz M, Vallieres E, et al. Pulmonary resection of nonsmall cell lung cancer (NSCLC) can be performed safely following definitive chemoradiotherapy. J Thorac Oncol 2009; 4:S301.
39. Pisters K, Evans WK, Azzolli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for stages I-IIIA resectable non-small-cell lung. Cancer guideline. J Clin Oncol 2007; 25:5506-5518 (Pubitemid 350232227)
40. National Collaborating Centre for Acute Care February 2005. Diagnosis and treatment of lung cancer. National Collaborating Centre for Acute Care. London. www.rcseng.ac.uk
41. D'Addario G, Felip E, on behalf of the ESMO Guidelines Working Group. Nonsmall-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl. 2):ii39-ii40.
42. NCCN clinical practice guidelines in oncology: nonsmall cell lung cancer. v.2. 2009. http://www.nccn.org/professionals/physician gls/PDF/nscl.pdf. [Accessed 2 January 2009].